Anlon Healthcare Ltd
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in the manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).[1]
- Market Cap ₹ 684 Cr.
- Current Price ₹ 129
- High / Low ₹ 148 / 87.0
- Stock P/E 33.3
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 24.8 %
- ROE 40.4 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 51.9%
Cons
- Promoter holding has decreased over last quarter: -17.6%
- Company might be capitalizing the interest cost
- Company has high debtors of 228 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE IPO
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 16 | 57 | 113 | 66 | 120 | |
| 21 | 52 | 100 | 51 | 88 | |
| Operating Profit | -5 | 6 | 13 | 16 | 33 |
| OPM % | -32% | 10% | 11% | 24% | 27% |
| 0 | 0 | 0 | 0 | 0 | |
| Interest | 3 | 4 | 4 | 4 | 4 |
| Depreciation | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | -10 | -0 | 7 | 10 | 27 |
| Tax % | 3% | 0% | 17% | 1% | 24% |
| -10 | -0 | 6 | 10 | 21 | |
| EPS in Rs | -8.53 | -0.09 | 4.85 | 6.04 | 5.15 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 28% |
| TTM: | 81% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 473% |
| TTM: | 112% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 52% |
| Last Year: | 40% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 16 | 40 |
| Reserves | -10 | -10 | -5 | 5 | 41 |
| 54 | 62 | 70 | 81 | 67 | |
| 16 | 21 | 34 | 26 | 34 | |
| Total Liabilities | 71 | 85 | 112 | 128 | 181 |
| 29 | 27 | 26 | 27 | 23 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 2 | 4 | 1 | 1 |
| 43 | 56 | 82 | 100 | 158 | |
| Total Assets | 71 | 85 | 112 | 128 | 181 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| -15 | -2 | -3 | -3 | -23 | |
| -2 | -0 | -0 | -3 | 3 | |
| 16 | 3 | 2 | 8 | 19 | |
| Net Cash Flow | -2 | 1 | -1 | 2 | -1 |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 132 | 130 | 142 | 213 | 228 |
| Inventory Days | 669 | 225 | 112 | 452 | 246 |
| Days Payable | 409 | 128 | 105 | 217 | 96 |
| Cash Conversion Cycle | 392 | 226 | 149 | 448 | 377 |
| Working Capital Days | 185 | 163 | 122 | 261 | 292 |
| ROCE % | 7% | 15% | 15% | 25% |
Documents
Announcements
-
Board Meeting Intimation for Consider And Approve Proposal For Purchase Of Immovable Property.
2d - Board meeting on Sep 27, 2025 to consider purchasing commercial office in Rajkot.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
23 Sep - Of Investor Meet as per Regulations 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on your record. Thank you.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
22 Sep - Management to meet SEEBERG Pvt Ltd online on Sep 25, 2025 at 4:00 PM IST
-
Announcement As Per Regulation 30 Of SEBI LODR, Regulations, 2015 For Development Of New Product.
20 Sep - Developed Artemether and Lumefantrine anti-malarials; expected November 2025.
-
Clarification On Price Movement Regarding Letter Received From L/SURV/ONL/PV/AJ/ 2025-2026 / 3092
18 Sep - Sept 18, 2025: Informed BSE/NSE of compliance; no undisclosed price-sensitive information.
Business Profile[1]
Anlon Healthcare is a chemical manufacturing company engaged in:
a) Pharmaceutical Intermediates – high-purity intermediates used as raw material/starting material in APIs.
b) Active Pharmaceutical Ingredients (APIs) – raw material for finished dosage formulations (tablets, capsules, ointments, syrups, etc.), nutraceuticals, personal care, and veterinary products.
c) It recently expanded into custom manufacturing services for complex/novel chemical compounds, including high-purity chemicals.